Your session is about to expire
← Back to Search
Daratumumab for Bladder and Kidney Cancer
Study Summary
This trial is testing the safety and effectiveness of daratumumab in patients with metastatic renal cell carcinoma or muscle invasive bladder cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
In what cases is Nephrectomy utilized as a treatment option?
"Nephrectomy is a procedure employed to treat multiple myeloma, refractory cases of the same cancer and cell transplants. Additionally, it has been used in combination with biological response modifiers for therapeutic effect."
Have past experiments included Nephrectomy as an element?
"Currently, there are 140 ongoing trials investigating Nephrectomy. Out of these studies, 26 have progressed to Phase 3. Although most occur in Harrison, New york, 5582 other research sites across the world are also running tests for this procedure."
Are fresh participants still being enrolled into this research project?
"Recruitment for this clinical trial has since ceased. It was posted on May 29th 2018, with the latest data being updated on September 22nd 2022. If you are seeking an alternative study, there are 2894 trials involving carcinoma and 140 nephrectomy trials currently looking for participants."
What is the exact size of the cohort engaging in this medical research?
"This trial is not currently accepting new patients. It was initially posted on the 29th of May 2018 and most recently updated in September 2022. If you are seeking alternate studies, there are 2894 trials recruiting participants with carcinoma and 140 trails for Nephrectomy that have active recruitment programs."
Share this study with friends
Copy Link
Messenger